2CBCB-NBOMe

From Wikipedia, the free encyclopedia
Jump to: navigation, search
2CBCB-NBOMe
2CBCB-NBOMe-skeletal.svg
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
Formula C19H22BrNO3
Molar mass 392.286 g/mol
3D model (JSmol)
 NYesY (what is this?)  (verify)

2CBCB-NBOMe (NBOMe-TCB-2) is a compound indirectly derived from the phenethylamine series of hallucinogens, which was discovered in 2007 at Purdue University as part of the ongoing research program of the team led by David Nichols focusing on the mapping of the specific amino acid residues responsible for ligand binding to the 5HT2A receptor. 2CBCB-NBOMe acts as a potent and selective agonist for the 5-HT2A and 5-HT2C receptors, with a Ki of 0.27nM at the human 5-HT2A receptor, a similar potency to other agonists such as TCB-2, NBOMe-2C-I and Bromo-DragonFLY.[1]

Analogues and derivatives[edit]

Legality[edit]

United Kingdom[edit]

This substance is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971.[2]


United States[edit]

2CBCB-NBOMe is a controlled substance in Vermont as of January 2016.[3]

References[edit]

  1. ^ Braden, Michael Robert (2007). Towards a biophysical understanding of hallucinogen action (PhD.). Purdue University. 
  2. ^ "The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014". www.legislation.gov.uk. 
  3. ^ "Regulated Drugs Rule" (PDF). Vermont Department of Health. Retrieved 14 October 2015.